Despite fewer people smoking and effective therapies for hypertension and high cholesterol, cardiovascular disease (CVD) remains the number one cause of death worldwide.¹

This epidemic is driven by demographic factors like an aging population, decreasing mortality from other factors (such as infectious disease), and rising rates of obesity—which can drive the progression of metabolic diseases, such as Type 2 diabetes, and lead to the “metabolic syndrome,” a constellation of risk factors that increase an individual’s risk for heart disease and other health problems.^2-6

We believe that a comprehensive program is needed to address cardiometabolic disease and the underlying biology responsible for its onset and progression.

Today, we’re focused on investigating the metabolic abnormalities that increase the likelihood of cardiometabolic diseases; working to develop potential therapies for these diseases, which are driven by an abnormal metabolic state; and seeking ways to protect the heart itself, by trying to alter the way it responds to this dysregulated metabolic environment.

This includes more potential therapies targeted to specific metabolic pathways in the body, as well as therapies that are a combination of two or more drugs, which could bring additional benefits to patients.

Our early discovery efforts are focused on obesity, type 2 diabetes, insulin resistance, non-alcoholic fatty liver disease/non-alcoholic steatohepatitis (NASH), and metabolic conditions such as cachexia, a form of unintentional weight loss and muscle-wasting often experienced with cancer and other serious illnesses.

Learn about our dedication to research and collaboration across healthcare in support of patients impacted by cardiometabolic disease.